Dare Bioscience DARE Income Statement (2013-2026)

NASDAQ DARE
$0.81 -0.02 (-1.84%)
At close: Aug 20, 2026 · 4:00 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Revenue & cost
Revenue (Quarter)
10.00M1.00M1.81M0.01M0.02M0.04M-0.06M0.03M-0.02M0.00M1.02M0.19M
Cost of Revenue (Quarter)
0.01M-0.01M0.30M0.32M
Gross Profit (Quarter)
1.00M0.00M0.02M0.04M-0.06M0.03M-0.02M0.00M0.73M-0.13M
Operating items
Research & Development (Quarter)
7.34M10.43M7.12M5.81M6.80M4.46M12.98M5.02M6.04M6.67M3.80M3.35M4.93M2.68M3.34M2.30M1.43M1.18M0.62M0.24M
Selling, General & Administrative (Quarter)
1.80M2.21M2.40M2.57M2.79M2.65M3.23M3.34M2.92M2.70M3.15M2.67M2.45M2.04M2.00M2.31M2.38M2.50M1.58M2.59M
Other Operating Expenses (Quarter)
0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.01M-0.01M
Operating Expenses (Quarter)
9.16M12.67M9.54M8.40M9.62M7.14M16.23M8.38M8.99M9.40M6.98M6.03M7.38M4.72M5.32M4.61M3.81M3.67M2.20M2.84M
Operating Income (Quarter)
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.02M-7.36M-4.68M-5.39M-4.58M-3.83M-3.67M-1.47M-2.97M
EBIT (Quarter)
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.02M-7.36M-4.68M-5.39M-4.58M-3.83M-3.67M-1.47M-2.97M
Non-operating items
Interest & Investment Income (Quarter)
0.09M0.16M
Other Non Operating Income (Quarter)
0.00M834.000.00M0.03M0.12M0.29M0.34M0.23M0.10M0.11M-0.73M-0.11M-0.02M1.84M0.20M-0.19M0.11M-0.28M-0.01M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-9.28M-12.79M-9.66M-8.52M0.30M-7.22M-16.30M-8.49M-9.09M-8.50M-5.57M-6.14M-7.58M-4.91M-5.35M-7.00M-5.95M-5.78M-1.64M-3.89M
Profit After Tax (Quarter)
-9.16M-12.73M-9.61M-8.40M0.41M-7.02M-15.94M-8.04M-8.76M-8.31M-4.99M-6.76M12.91M-4.68M-5.50M-4.38M-4.02M-3.56M-1.47M-2.98M
Income from Continuing Operations (Quarter)
-9.28M-12.79M-9.66M-8.52M0.30M-7.22M-16.30M-8.49M-9.09M-8.50M-5.57M-6.14M-7.58M-4.91M-5.35M-7.00M-5.95M-5.78M-1.64M-3.89M
Consolidated Net Income (Quarter)
-9.28M-12.79M-9.66M-8.52M0.30M-7.22M-16.30M-8.49M-9.09M-8.50M-5.57M-6.14M-7.58M-4.91M-5.35M-7.00M-5.95M-5.78M-1.64M-3.89M
Income towards Parent Company (Quarter)
-9.28M-12.79M-9.66M-8.52M0.30M-7.22M-16.30M-8.49M-9.09M-8.50M-5.57M-6.14M-7.58M-4.91M-5.35M-7.00M-5.95M-5.78M-1.64M-3.89M
Net Income towards Common Stockholders (Quarter)
-9.28M-12.67M-9.54M-8.40M0.30M-7.02M-15.94M-8.04M-9.09M-8.30M-8.76M-6.14M-7.58M-4.91M-5.35M-7.00M-5.95M-5.78M-1.64M-3.89M
Additional items
EPS (Basic) (Quarter)
-2.21-2.15-1.87-1.200.04-0.99-2.26-1.13-1.26-1.09-1.20-0.73-0.90-0.58-0.63-0.80-0.67-0.45-0.15-0.26
EPS (Diluted) (Quarter)
-2.21-2.15-1.87-1.200.04-0.99-2.26-1.13-1.26-1.09-1.20-0.73-0.89-0.58-0.63-0.80-0.67-0.45-0.15-0.26
Shares Outstanding (Quarter)
4.20M5.90M5.10M7.00M7.06M7.07M7.05M7.13M7.20M7.59M7.28M8.38M8.41M8.53M8.50M8.76M8.87M12.76M11.18M14.89M
Shares Outstanding (Diluted) (Quarter)
4.20M5.90M5.10M7.00M7.11M7.07M7.05M7.13M7.20M7.59M7.28M8.38M8.48M8.53M8.50M8.76M8.87M12.76M11.18M14.89M
Shares Outstanding (Entity) (Quarter)
4.78M6.38M5.10M7.00M7.07M7.07M7.07M7.18M7.22M8.19M8.33M8.38M8.55M8.55M8.70M8.85M9.03M13.93M11.18M15.17M
EBITDA (Quarter)
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.02M-7.36M-4.68M-5.39M-4.58M-3.83M-3.67M-1.47M-2.97M
Interest Expenses (Quarter)
0.11M0.12M0.12M0.12M0.08M0.08M0.07M0.10M0.10M0.11M0.40M0.21M0.22M0.23M-0.04M2.58M2.12M2.11M0.17M0.92M